Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HCN4 | Q9Y3Q4 | 4/20 | 0.58 |
| ▸ | HCN1 | O60741 | 4/20 | 0.58 |
| ▸ | KCNA3 | P22001 | 8/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2469491 | 0.88 | MEN1 (0.57) | MEN1KMT2AALDH1A1TP53GLA | |
| SCHEMBL12195395 | 0.85 | NPFFR1 (0.58) | MEN1KMT2AALDH1A1TP53GLA | |
| SCHEMBL2471540 | 0.84 | MEN1 (0.52) | MEN1KMT2AALDH1A1TP53GLA | |
| SCHEMBL13593952 | 0.82 | MEN1 (0.50) | MEN1KMT2AALDH1A1TP53GLA | |
| SCHEMBL2467869 | 0.82 | KCNA3 (0.53) | MEN1KMT2AALDH1A1TP53GLA | |
| SCHEMBL2471064 | 0.81 | SLC6A9 (0.56) | MEN1KMT2AALDH1A1TP53GLA | |
| SCHEMBL3904049 | 0.81 | MEN1 (0.97) | MEN1KMT2AALDH1A1KCNA3 | |
| SCHEMBL2867565 | 0.80 | NPC1 (0.57) | MEN1KMT2AALDH1A1 | |
| SCHEMBL2861616 | 0.79 | LMNA (0.58) | ALDH1A1TP53P2RX7 | |
| SCHEMBL3455503 | 0.79 | MEN1 (1.00) | MEN1KMT2AALDH1A1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | LLOYD JOHN | 2005-10-20 | — | — | US | disclosed |
| EP-1507504-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040072880-A1 | Cycloalkyl inhibitors of potassium channel function | ICAGEN, INC. | 2004-04-15 | — | — | US | disclosed |
| WO-2003063797-A2 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | KCNJ2, KCNN3, KCNQ5 | MEN1 4430/4885KMT2A 1396/4885ALDH1A1 4075/4885 |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | MEN1 4430/4885KMT2A 1396/4885ALDH1A1 4075/4885 |
| US-20040072880-A1 | Cycloalkyl inhibitors of potassium channel function | KCNN1, KCNN2, KCNH2 | MEN1 4044/4885KMT2A 1835/4885ALDH1A1 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.